10-Q: Xtant Medical Swings to Profit, Boosts Revenue 18%

Xtant Medical Holdings, Inc. reported a significant financial turnaround in Q2 2025, achieving net income and substantial revenue growth, while announcing strategic divestitures of its Coflex/CoFix and international hardware businesses.

Summary

• Total revenue for the three months ended June 30, 2025, increased by 18% to $35.4 million, up from $29.9 million in the prior year period.
• Total revenue for the six months ended June 30, 2025, increased by 18% to $68.3 million, up from $57.8 million in the prior year period.
• Net income for the three months ended June 30, 2025, was $3.55 million, a significant improvement from a net loss of $3.86 million in the same period of 2024.
• Net income for the six months ended June 30, 2025, was $3.61 million, compared to a net loss of $8.26 million in the comparable prior year period.
• Gross profit margin improved to 68.6% for Q2 2025 (from 62.1% in Q2 2024) and 65.2% for the six months ended June 30, 2025 (from 62.1% in the prior year period), driven by sales mix, greater scale, improved production efficiency, and reduced product costs.
• Operating expenses decreased by 9% for the three months and 8% for the six months ended June 30, 2025, primarily due to reduced sales commissions and compensation expenses.
• Net cash provided by operating activities for the first six months of 2025 was $2.55 million, a substantial improvement from net cash used of $10.84 million in the same period of 2024.
• The company entered into agreements to sell its Coflex/CoFix business in the U.S. and its international hardware business (Paradigm Spine GmbH) to Companion Spine, LLC for a total purchase price of $19.2 million.
• A non-refundable cash deposit of $2.5 million was received for the Coflex/CoFix transaction, with the remaining balance to include up to $6.8 million cash and an $8.2 million unsecured promissory note maturing December 31, 2025.
• Nantahala Capital Management, LLC acquired OrbiMed's entire stake in April 2025, now holding approximately 49.1% of the company's common stock.
• The company expects its current cash and anticipated operating cash flows, along with available credit facilities, to be sufficient to meet cash requirements through at least August 2026.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong financial performance, including a swing to profitability, significant revenue growth, and improved margins. Strategic divestitures are also a positive step towards streamlining the business. However, the score is tempered by the inherent risks associated with the completion of these divestitures (buyer financing, promissory note), potential negative impacts from future CMS reimbursement policy changes, and the concentration of ownership by Nantahala Capital, which introduces governance risks.

Positives

• Achieved significant financial turnaround with net income of $3.55 million in Q2 2025 and $3.61 million for the first six months of 2025, compared to substantial losses in prior periods.
• Experienced strong revenue growth of 18% for both the three and six months ended June 30, 2025, reaching $35.4 million and $68.3 million respectively.
• Gross profit margins significantly improved to 68.6% in Q2 2025 and 65.2% for the first six months of 2025, reflecting better sales mix, increased scale, improved production efficiency, and reduced product costs.
• Operating expenses decreased by $1.9 million for the three months and $3.5 million for the six months ended June 30, 2025, demonstrating effective cost management.
• Generated positive net cash from operating activities of $2.55 million for the first six months of 2025, a substantial improvement from negative operating cash flow in the prior year.
• Strategic divestitures of the Coflex/CoFix and international hardware businesses for $19.2 million are expected to streamline operations and improve liquidity, with a $2.5 million non-refundable deposit already received.
• Successfully secured new license agreements, contributing $4.975 million in license revenue in Q2 2025 and $8.595 million for the first six months of 2025.
• Maintained compliance with all covenants under its term loan and revolving line of credit agreements as of June 30, 2025.

Negatives

• The completion of the Coflex/CoFix and Paradigm transactions is subject to the buyer obtaining financing, introducing uncertainty and potential delays.
• A significant portion of the Coflex/CoFix purchase price ($8.2 million) will be paid via an unsecured promissory note maturing December 31, 2025, posing a collection risk.
• CMS policy changes, including proposed fixed reimbursement rates of $125.38 per square centimeter for skin substitutes starting January 1, 2026, could negatively impact future revenue from SimpliMax and SimpliGraft products.
• Increased net cash used in investing activities for the first six months of 2025, primarily due to increased purchases of property and equipment.
• Shift from net cash provided by financing activities ($11.6 million in 2024) to net cash used by financing activities ($0.3 million in 2025) due to reduced revolver borrowings.
• The company may require or seek additional capital prior to August 2026, and there is no assurance that such financing will be available on acceptable terms or without diluting current stockholders.

Risks

• Delays or termination of the Coflex/CoFix and Paradigm transactions, including the buyer's inability to obtain sufficient financing.
• Diversion of management's attention to complete the divestiture transactions, potentially impacting core business operations.
• Potential loss of key employees, suppliers, customers, distributors, and independent sales agents as a result of the announced and/or completed transactions.
• Adverse impact on business, financial condition, and operating results if the transactions are not completed or do not achieve anticipated financial effects.
• Incurrence of higher-than-anticipated transaction costs, reducing net proceeds from the divestitures.
• Risk of the buyer failing to pay the $8.2 million unsecured promissory note from the Coflex/CoFix transaction.
• Adverse impact on the Coflex/CoFix Business and international hardware business if the divestiture agreements are terminated.
• Inaccurate assessment of unanticipated costs and liabilities associated with the transactions, including potential litigation and adverse tax consequences.
• Nantahala Capital Management, LLC's significant ownership (49.1%) allows substantial influence over corporate decisions, potentially misaligned with other stockholders' interests.
• Potential adverse effect on the common stock's market price due to sales of substantial amounts of shares by major stockholders or the perception of such sales, especially given low trading volume and public float.
• Risk of delisting from the NYSE American Exchange if the trading price of common stock decreases to abnormally low levels.
• Impact of CMS policy changes on reimbursement for cellular and tissue-based products (e.g., SimpliMax, SimpliGraft), potentially reducing future revenue.
• Dependence on and ability to retain and recruit independent sales agents and distributors.
• Ability to obtain and maintain regulatory approvals in the United States and abroad.
• Ability to remain accredited with the American Association of Tissue Banks and secure sufficient donor cadavers.
• Ability to obtain and maintain government and third-party coverage and reimbursement for products.
• Ability to maintain sufficient liquidity to meet financial covenants under credit agreements and fund operations, and the ability to obtain additional financing on reasonable terms when needed.

Future Outlook

The company anticipates its current cash, operating cash flows, and available credit facilities will be sufficient to meet cash requirements through at least August 2026. It may seek additional financing if market conditions are favorable, even if not immediately needed. The completion of the Coflex/CoFix and Paradigm transactions is expected in the third quarter of 2025, contingent on the buyer obtaining financing. CMS policy changes, including proposed fixed reimbursement rates for skin substitutes, are scheduled for implementation on January 1, 2026, and could impact future revenue. The company is evaluating the impact of the One Big Beautiful Bill Act (OBBBA) on its financial statements, with no material change to its effective income tax rate or net deferred federal income tax assets anticipated due to a full valuation allowance.

Management Comments

• Management believes the company's strategic priorities, including controlling its supply chain and becoming less reliant on external production, will allow it to be a larger and more diverse producer of biologics.
• Management is focused on four key growth initiatives: introducing new products (e.g., Trivium), expanding the distribution network, penetrating adjacent markets, and leveraging its growth platform with technology and strategic acquisitions.
• Management acknowledges that the completion of the Coflex/CoFix and Paradigm transactions is expected in the third quarter of 2025, but no assurance can be provided that the closings will not be delayed or will occur.
• Management does not anticipate a material effect on the business from recently enacted or to be effective tariffs announced by the current U.S. Presidential administration.
• Management believes that its $7.0 million of cash and cash equivalents as of June 30, 2025, together with anticipated operating cash flows and amounts available under the Facilities, will be sufficient to meet anticipated cash requirements through at least August 2026.

Industry Context

The medical technology industry, particularly orthobiologics and spinal implants, is subject to evolving regulatory landscapes and reimbursement policies. The announced CMS policy changes regarding skin substitutes, proposing a fixed payment approach, reflect a broader trend of cost containment and value-based care initiatives within the U.S. healthcare system. This could put pressure on pricing and margins for companies in this segment. The strategic divestitures indicate a focus on core profitable segments and a move away from less synergistic or lower-margin product lines, a common strategy in a competitive and consolidating market. The company's emphasis on internal production and supply chain control aligns with industry efforts to enhance efficiency and reduce reliance on external factors.

Comparison to Industry Standards

• The company's gross margin improvement to 68.6% in Q2 2025 is strong for the medical device and biologics sector, indicating efficient production and favorable product mix. For comparison, leading medical device companies often report gross margins in the 60-75% range, suggesting Xtant Medical is performing competitively in this aspect.
• The shift from significant operating cash outflow to positive operating cash flow ($2.55 million for YTD Q2 2025) demonstrates a substantial operational improvement, aligning with the performance of more mature and financially stable companies in the industry.
• The strategic divestiture of the Coflex/CoFix and international hardware businesses for $19.2 million, while specific to Xtant, reflects a broader industry trend where companies rationalize their product portfolios to focus on high-growth or higher-margin areas. This is comparable to portfolio optimization strategies seen at larger players like Medtronic or Stryker, albeit on a smaller scale.
• The company's reliance on independent sales agents and distributors is a common model in the medical device industry, particularly for smaller companies, but it also introduces risks related to sales force effectiveness and retention, similar to challenges faced by peers like SeaSpine or Orthofix.
• The impact of CMS policy changes on reimbursement for skin substitutes is an industry-wide concern, affecting all companies with similar product lines. The proposed fixed price of $125.38 per square centimeter for skin substitutes could significantly alter the revenue landscape for products like SimpliMax and SimpliGraft, potentially impacting Xtant Medical similarly to how it would affect competitors in the wound care or biologics space.

Corporate Governance

Legal Proceedings

• The company is subject to potential liabilities under government regulations and various claims and legal actions arising in the ordinary course of business, including commercial, product liability, intellectual property, and employment matters.
• The company assesses contingencies to determine the probability and range of possible loss for potential accrual in financial statements, and has adequately accrued an amount for contingent liabilities currently in existence.
• Litigation is inherently unpredictable, and unfavorable resolutions could occur, potentially exceeding current accruals and materially affecting cash flows or results of operations in any particular period.

Related Party Transactions

• OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP (affiliated with OrbiMed Advisors LLC) previously beneficially owned 52.6% of the company's common stock as of March 31, 2025.
• In April 2025, OrbiMed sold all of its shares to several investors in a private secondary resale transaction.
• Funds affiliated with Nantahala Capital Management, LLC, an existing stockholder, purchased 57.0 million shares from OrbiMed, resulting in Nantahala holding 49.1% of the issued and outstanding shares.
• A family member of Stavros Vizirgianakis, a Board member, also participated in the transaction and purchased shares from OrbiMed.
• The company was not a party to the stock purchase agreement but entered into a registration rights agreement with the purchasers to facilitate the resale of shares, agreeing to file a shelf resale registration statement and indemnify selling stockholders from certain liabilities, and pay all fees and expenses incident to its performance.

Stakeholder Impact

• **Shareholders**: Experienced a significant improvement in net income and EPS, indicating a positive financial turnaround. However, potential dilution from future capital raises and the concentration of voting control by Nantahala Capital could affect other stockholders' influence and the market price.
• **Employees**: The company's focus on internal production and growth initiatives could lead to job stability or creation. However, the strategic divestitures of the Coflex/CoFix and international hardware businesses carry a risk of potential loss of key employees associated with those segments.
• **Customers**: The divestiture of Coflex/CoFix and international hardware businesses means a change in supplier for those specific products, which could lead to disruption or transition challenges. New product introductions aim to benefit customers with expanded offerings.
• **Suppliers**: The company's increased focus on controlling its supply chain and internal production may alter relationships with certain third-party suppliers, potentially reducing reliance on some external manufacturers.
• **Creditors**: The company's improved financial performance and positive operating cash flow enhance its ability to service its debt. The prepayment of $9.6 million to MidCap from divestiture proceeds will reduce outstanding debt, improving the company's credit profile, though the unsecured promissory note from the buyer introduces a new credit risk.

Next Steps

• Complete the sale of the Coflex/CoFix Business and Paradigm Spine GmbH to Companion Spine, LLC, expected in Q3 2025.
• Monitor and adapt to the final CMS rules for CY 2026 Physician Fee Schedule (PFS) and Hospital Outpatient Prospective Payment System (OPPS) regarding skin substitute reimbursement, scheduled for implementation on January 1, 2026.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on financial condition and results of operations, with anticipated impact to be included in Q3 2025 financial statements.
• Continue to implement four key growth initiatives: introducing new products, expanding the distribution network, penetrating adjacent markets, and leveraging the growth platform with technology and strategic acquisitions.
• Potentially seek additional financing through equity or debt, or strategic transactions, if needed or if market conditions are favorable.

Key Dates

Recommendation

The company has demonstrated a strong financial turnaround, moving from significant losses to profitability with robust revenue growth and improved gross margins. The strategic divestitures are positive steps towards streamlining the business and improving liquidity. However, the completion of these divestitures is contingent on buyer financing and includes an unsecured promissory note, introducing execution risk. Furthermore, potential adverse CMS policy changes for key products starting in 2026 pose a significant future revenue uncertainty. While current results are strong, these forward-looking risks and the concentrated ownership by Nantahala Capital warrant a cautious 'hold' recommendation for a seasoned investor, advising to monitor the successful completion of the divestitures and the finalization of CMS reimbursement policies.

Keywords

Orthobiologics, Spinal Implants, Medical Technology, SEC Filing, Quarterly Report, Financial Results, Revenue Growth, Net Income, Divestiture, Asset Sale, Licensing, CMS Policy, Nantahala Capital, Corporate Governance, Risk Factors, Healthcare, Surgical Instruments